|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial显示文摘BACKGROUND The optimal way to home-monitor patients with inflammatory bowel disease(IBD)for disease progression or relapse remains to be found.AIM To determine whether an electronic health(eHealth)screening procedure for disease activity in IBD should be implemented in clinical practice,scheduled every third month(3M)or according to patient own decision,on demand(OD).METHODS Adult IBD patients were consecutively randomized to 1-year open-label eHealth interventions(3M vs OD).Both intervention arms were screening for disease activity,quality of life and fatigue and were measuring medical compliance with the constant care web-application according to the screening interventions OD or 3M.Disease activity was assessed using home measured fecal calprotectin(FC)and a disease activity score.RESULTS In total,102 patients were randomized(n=52/503M/OD)at baseline,and 88 patients completed the 1-year study(n=433M;n=45 OD).No difference in the two screening procedures could be found regarding medical compliance(P=0.58),fatigue(P=0.86),quality of life(P=0.17),mean time spent in remission(P>0.32),overall FC relapse rates(P=0.49),FC disease courses(P=0.61),FC time to a severe relapse(P=0.69)and remission(P=0.88)during 1 year.Median(interquartile range)numbers of FC home-monitoring test-kits used per patient were significantly different,3M:6.0(5.0-8.0)and OD:4.0(2.0-9.0),P=0.04.CONCLUSION The two eHealth screening procedures are equally good in capturing a relapse and bringing about remission.However,the OD group used fewer FC home testkits per patient.Individualized screening procedures can be recommended for adult IBD patients in clinical web-practice. | Dorit Vedel Ankersen Petra Weimers Dorte Marker Mette Bennedsen Sanaz Saboori Kristine Paridaens Johan Burisch Pia Munkholm | 2019 | World Journal of Gastroenterology2019，25，40： | 2 |
| 2 | Spontaneous congenital nonpigmented epithelial cysts of the iris stroma显示文摘 | Paridaens A Deuble K Mccartney A | 1992 | Br J Ophthalmol1992，76，： | 1 |
| 3 | Bicanalicular silicone intub ation in acquired partialnasolacrimal ductob struction显示文摘 | Bieyen I’Paridaens AD | 2008 | Bull Soc Beige Ophlalmo2008，3，4： | 1 |
| 4 | Proteases and metastasis: clinical relevance nowadays? 显示文摘 | Decock J Paridaens R Cufer T | 2005 | Curr Opin Oncol2005，17，1： | 1 |
| 5 | Transcon- junctival orbital decompression in Graves' ophthalmopathy :lateral wall approach ab interno显示文摘 | Dion A Paridaens Karin Verlmeff Dimitri Bouwens | 2000 | Br J Ophthahnol2000，84，7： | 1 |
| 6 | PhaseⅢstudy comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women:The european organisation for research and treatment of cancer breast cancer cooperative group显示文摘 | Paridaens R J Dirix L Y Beex L V | 2008 | J Clin Oncol2008，26，30： | 1 |
| 7 | Efficacy and side effects of swinging eyelid' orbital decompression in Graves' orbitopathy:a proposal for standardized evaluation of diplopia 显示文摘 | Paridaens D Lie A Grootendorst RJ | 2006 | Eye2006，20，2： | 1 |
| 8 | Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer:a European Organization for Research and Treatment of Cancer Randomized Study with cross-over显示文摘 | Biganzoli L Bruning P | 2000 | J Clin Oncol2000，18，4： | 1 |
| 9 | Mature results of a randomized phase Ⅱ multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer显示文摘 | Paridaens R Dirix L Lohrisch C | 2003 | Ann Oncol2003，14，9： | 1 |
| 10 | Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors:final results of phase Ⅱ Swiss Group for Clinical Cancer Research Trial显示文摘 | Perey L Paridaens R Hawle H | 2007 | Ann Oncol2007，18，1： | 1 |
| 11 | First mature analysis of the intergroup Exemestane study显示文摘 | Coombes RC Paridaens R Jassem J | 2006 | J Clin Oncol2006，24，18： | 1 |
| 12 | Paclitaxel versus doxorubicin as firstline single agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with crossover 显示文摘 | Paridaens R | 2000 | J Clin Oncol2000，18，4： | 1 |
| 13 | PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves'ophthalmopathy patients显示文摘 | van Steensel L Hooijkaas H Paridaens D | | 0，，06： | 1 |
| 14 | An open label, multicenter study of outpatients capecitabine monotherapy in 631 patients with preteated advanced breast cancer显示文摘 | Venturini M Paridaens R Rossner D | 2007 | Oncology2007，72，12： | 1 |
| 15 | Scalability implications of virtual private networks显示文摘 | De Clercq J Paridaens O | 2002 | Communications Magazine IEEE2002，40，5： | 1 |
| 16 | Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves'ophthalmopathy显示文摘 | van Steensel L Paridaens D van Meurs M | | 0，，03： | 1 |
| 17 | A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood显示文摘 | Aerts J Wynendaele W Paridaens R | 2001 | Annal Oncol2001，12，1： | 1 |
| 18 | Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts:a potential treatment for Graves'ophthalmopathy显示文摘 | van Steensel L Paridaens D Schrijver B | 2009 | Invest Ophthalmol Vis Sci2009，50，7： | 1 |
| 19 | First line hormonal treatment(HT) for metastatic breast cancer(MBC) with exemestane(E) or tamoxifen(T) in postmenopausal patients(pts)-A randomized phase Ⅲ trial of the EORTC Breast Group显示文摘 | Paridaens R Therasse P Dirix L | 2004 | Proc Am Soc Clin Oncol2004，，： | 1 |
| 20 | An open-label,multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer显示文摘 | Venturini M Paridaens R Rossner D | 2007 | Oncology2007，72，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员